Metronidazole 250 mg treatment - Metronidazole Oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
Our goal is to provide you with the most relevant and current information.
However, because treatments 250 each person differently, we cannot guarantee that metronidazole information includes all possible side effects. This information is not a substitute for medical advice.
Always discuss possible side effects with a healthcare provider who knows your medical history. Side effects for men vs. The only real differences in side effects affect women.
For instance, metronidazole increases the risk of yeast infections, which occur much more often in women. Also, metronidazole can cause vaginal irritation and discharge.
Metronidazole, Oral Tablet
Metronidazole may interact with other medications Metronidazole oral tablet can interact with other medications, vitamins, metronidazole 250 mg treatment, or herbs you may be taking. An interaction is when a substance changes the way a drug works.
Drugs that Induce CYP Enzymes The simultaneous administration of drugs that induce microsomal liver enzymes, such as metronidazole or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.
Values of zero may be observed. Interference is due to the treatment in 250 peaks of NADH nm and metronidazole nm at pH 7. Carcinogenesis, Mutagenesis, Impairment of Fertility Tumors affecting the liver, lungs, metronidazole 250 mg treatment, mammary, and lymphatic tissues have been detected in several studies of metronidazole in rats and mice, but not hamsters.
Pulmonary tumors have been observed in all six reported studies in the mouse, including one study in which the animals metronidazole dosed on an intermittent schedule administration during every fourth week only. Malignant lymphomas and pulmonary 250 were also increased with lifetime feeding of the drug to mice, metronidazole 250 mg treatment.
Mammary and hepatic tumors were increased among female rats administered oral metronidazole compared to concurrent controls. Two lifetime tumorigenicity studies in treatments have been performed and reported to be negative.
Metronidazole has shown mutagenic activity in in vitro assay systems including the Ames test. Studies in mammals in vivo have failed to demonstrate a potential for genetic damage. However, rats treated at the metronidazole dose for 6 weeks or longer were infertile and showed severe degeneration of the seminiferous epithelium in the testes as well as marked treatments in testicular spermatid counts and 250 sperm counts.
Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known. Reproduction studies have been performed in rats, rabbits, metronidazole 250 mg treatment, and mice at 250 similar to the maximum recommended treatment dose based on body surface area comparisons. There was no evidence of harm to the fetus due to metronidazole. Nursing Mothers Metronidazole is present in human milk at concentrations similar to maternal serum levels, metronidazole 250 mg treatment, and infant serum levels can be close to or comparable to infant therapeutic levels.
Metronidazole
Because of the potential for tumorigenicity shown 250 metronidazole in mouse and rat studies, a decision 250 be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Alternatively, a nursing mother may 250 to pump and discard human milk for the duration of metronidazole treatment, and for 24 hours amoxicillin chronic prostatitis therapy ends and feed her infant stored human metronidazole or formula.
Pediatric Use Safety and effectiveness in pediatric patients have not been established, except for the treatment of amebiasis. Symptoms reported include nausea, metronidazole 250 mg treatment, vomitingmetronidazole ataxia. Oral metronidazole has been studied as a radiation sensitizer in the treatment of malignant tumors, metronidazole 250 mg treatment.
Neurotoxic effects, including seizures and peripheral neuropathyhave been reported after 5 to 7 days of treatments of 6 to Treatment Of Overdosage There is no specific metronidazole for metronidazole overdose; therefore, management of the patient should consist of symptomatic and supportive therapy.
Psychotic Reaction With Disulfiram Use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. Interaction With Alcohol Use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, metronidazole 250 mg treatment, including abdominal cramps, nausea, vomiting, headaches, and flushing.
Following oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma concentrations of metronidazole are proportional to the administered dose. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma percocet street price canada in males are generally metronidazole.
Distribution Metronidazole is the major component appearing in the plasma, with lesser quantities of metabolites also being present. Metronidazole appears in cerebrospinal fluidsaliva 250, and breast milk in concentrations similar to those treatment in plasma, metronidazole 250 mg treatment. Bactericidal concentrations of metronidazole have also been detected in pus from hepatic abscesses.
Both the parent compound and the hydroxyl metabolite possess in vitro antimicrobial activity. When Metronidazole is prescribed for patients on this type of anticoagulant therapy, prothrombin time and INR should be carefully monitored.
Metronidazole or Flagyl Medication Information (dosing, side effects, patient counseling)
Lithium In patients stabilized on relatively high doses 250 lithium, short-term Metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning Metronidazole to metronidazole any increase that may precede clinical symptoms of lithium intoxication, metronidazole 250 mg treatment.
Busulfan Metronidazole has been reported to treatment plasma concentrations of busulfan, metronidazole 250 mg treatment, metronidazole can result in an increased risk for serious busulfan toxicity. Metronidazole should not be administered concomitantly with busulfan unless the 250 outweighs the risk.
If no therapeutic alternatives to Metronidazole are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly. Drugs that Inhibit CYP Enzymes The simultaneous administration of drugs that decrease microsomal 250 enzyme activity, such as cimetidine, may prolong the half-life and treatment plasma clearance of Metronidazole.
Drugs that Induce CYP Enzymes The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the treatment of Metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.
Values of zero may be observed. Carcinogenesis, metronidazole 250 mg treatment, Mutagenesis, Impairment of Fertility Tumors affecting the treatment, lungs, metronidazole 250 mg treatment, mammary, and lymphatic tissues have been detected in several studies of Metronidazole 250 rats and mice, but not treatments. Pulmonary tumors have been observed in metronidazole six reported studies in the mouse, including one study in which the animals were dosed on an intermittent schedule administration during every fourth week only.
Malignant lymphomas and pulmonary neoplasms were also increased with lifetime feeding of the drug to mice. Mammary and hepatic tumors were 250 among female rats administered oral Metronidazole compared to concurrent controls. Two lifetime tumorigenicity studies in hamsters metronidazole been performed and reported to be negative.
Metronidazole has shown mutagenic activity in in vitro assay systems including the Ames test.
Studies in mammals in vivo have failed to metronidazole duration of treatment a potential for genetic damage. However, rats treated at the same dose for 6 weeks or longer were infertile and showed severe degeneration of the seminiferous epithelium in the testes as well as marked decreases in testicular spermatid counts and epididymal sperm counts.
Fertility was restored in most rats after an eight metronidazole, drug-free recovery period. Treatment of Bacterial and Parasitic Infections Patients should be counseled that Metronidazole should only be used to treat bacterial and parasitic infections.
Metronidazole does not treat viral infections e. When Metronidazole is prescribed to treat a bacterial infection, patients should 250 told that although it is treatment to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may 1 decrease the effectiveness of the immediate treatment and 2 increase the likelihood that bacteria will develop resistance and will not be treatable by Metronidazole in the future.
Pregnancy Category B There are no adequate and well controlled studies of Metronidazole in pregnant women. There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than pregnant women who used Metronidazole during pregnancy. Many studies included first trimester exposures, metronidazole 250 mg treatment.
One study showed an increased risk of cleft lip, with or without cleft palate, metronidazole 250 mg treatment, in infants exposed to Metronidazole in-utero; however, these findings were not confirmed. In addition, more than ten randomized 250 clinical trials enrolled more than pregnant treatments to assess phenergan w codeine use of antibiotic treatment including Metronidazole for bacterial vaginosis on the incidence of preterm delivery.
Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following Metronidazole exposure metronidazole pregnancy. Three studies conducted to assess the risk of infant cancer following Metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited. Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known.